Overview
The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL) initiating ibrutinib in a routine clinical practice setting. HRQoL will be measured using functional assessment of cancer therapy - general scale (FACT-G).
Eligibility
Inclusion Criteria:
- Participants newly treated with ibrutinib for first line or relapsed CLL (treatment is being initiated or has been initiated within the last 8 days as a maximum)
- Participants agreed to follow the individual physical activity intervention (IPAI)
- Participants using or having access to a compatible and appropriate electronic device such as smartphone, laptop or tablet
- Participants with Internet access at home and email address
- Participants agreed to wear a connected watch 24 hours a day for all the duration of the study
Exclusion Criteria:
- Pregnant participants or planning to become pregnant while enrolled in this study
- Participants with inability or deemed unsafe to practice physical activity
- Participants who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the inclusion visit
- Participants who are currently involved in an interventional study
- Participants with probable difficulties in using the digital tool autonomously